(Reuters) – Eli Lilly said on Monday it has sued two medical spas for selling unapproved products claiming to contain tirzepatide, the main ingredient in its popular weight-loss medicine Zepbound.
The new lawsuits name Thrive Health and Wellness LLC and Valhalla Vitality LLC. Lilly said the companies were selling unapproved drugs and making false claims about efficacy, purity or safety.
Thrive Health and Valhalla Vitality both sell products that they say contain tirzepatide, according to the filings.
The complaint against Thrive was filed in the district court of Colorado and the complaint against Valhalla was filed in the Eastern District of New York.
The Indianapolis-based drugmaker has already sued more than two dozen medical spas, wellness centers and compounding pharmacies for selling products claiming to contain tirzepatide, which is also approved to treat type 2 diabetes under the brand name Mounjaro.
(Reporting by Manas Mishra in Bengaluru; Editing by Shounak Dasgupta)
Comments